WASHINGTON — The White House is reviewing a Health and Human Services policy that could temporarily ease federal restrictions on pharmacy compounding of certain peptides, moving a fast-growing wellness market closer to regulated access even though the products at issue have not been approved by the Food and Drug Administration for safety or effectiveness.

The proposal, titled “Interim Access Policy for Compounding Using Certain Peptides,” was received for review this week by the Office of Information and Regulatory Affairs, according to the federal regulatory docket. The posting identifies the action but does not disclose which substances it covers, what conditions pharmacies would have to meet or how long the interim approach would last. That missing detail is important because a temporary enforcement policy is not the same as a formal finding that a drug is safe, effective or approved for a particular use.

The Associated Press, citing two people familiar with the plan, reported that it would use enforcement discretion to allow pharmacies to compound some popular peptides, including BPC-157, while broader rulemaking proceeds. Reuters independently confirmed the submission and reported that outside FDA advisers had recommended loosening restrictions on six of seven peptides reviewed in July. HHS and FDA had not publicly released the policy text or commented on its substance as of Thursday evening.

What compounding does — and does not — mean

Drug compounding allows a pharmacist or physician to prepare a medication for a patient's specific clinical need when a suitable FDA-approved product is not available in the needed dose or form. It is a legitimate part of medical care, but the legal pathway differs sharply from approval of a manufactured drug. The FDA's compounding overview states that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before marketing.

Traditional pharmacies operating under Section 503A of the Federal Food, Drug and Cosmetic Act can qualify for exemptions from some federal requirements when they compound for identified patients and satisfy other conditions. When they start with a bulk substance that is neither part of an approved drug nor covered by an applicable U.S. Pharmacopeia or National Formulary monograph, that substance generally must appear on a federal list established through regulation. FDA has also used interim categories and enforcement policies while evaluating nominations.

That structure is designed to preserve individualized access without turning compounding into an alternative mass-market approval system. The distinction matters for peptides because chemical synthesis, storage and injection can introduce risks that are separate from whether the molecule might eventually prove useful. Purity, aggregation, sterility, dosing and immune reactions all depend on manufacturing and handling, not only on the proposed biological effect.

BPC-157 is the clearest test case

BPC-157, sometimes marketed as a “Wolverine” peptide, is promoted for injury recovery, pain and gastrointestinal conditions. It is not an FDA-approved drug. Much of the published evidence comes from laboratory and animal research, and a 2025 narrative review found promising preclinical signals but emphasized the need for rigorous human trials, standardized dosing and long-term safety data.

FDA scientists reached a cautious conclusion in a detailed briefing document prepared for the July Pharmacy Compounding Advisory Committee meeting. The staff said BPC-157 was not well characterized from a physicochemical perspective, that information about its safety and immunogenicity was limited, and that evidence was insufficient to determine effectiveness for ulcerative colitis, the clinical use evaluated in the review. FDA also noted that adverse-event reports are difficult to interpret because they may lack detail and involve other medications.

The agency's broader safety table identifies potential immunogenicity risks for BPC-157 and complexities involving peptide-related impurities and characterization of the active ingredient. Immunogenicity means the immune system may react to a substance; for peptides, aggregation or subtle impurities can change that risk. The existence of a signal does not establish that every compounded preparation will cause harm, but it explains why regulators focus on production controls and evidence rather than popularity alone.

The advisory vote was not a final approval

The FDA convened its Pharmacy Compounding Advisory Committee on July 23 and 24 to review BPC-157 and several other peptides, including emideltide, epitalon, KPV, MOTS-c, Semax and TB-500-related substances. The committee's recommendations inform the agency, but they do not themselves place a substance on the 503A bulks list or transform it into an approved drug.

Stanford Medicine researchers summarized the scientific tension after the meeting: in a public evidence review, they noted that the panel recommended loosening restrictions for six peptides despite the products remaining far from traditional approval and lacking the clinical testing expected for safety and efficacy. Supporters argue that pharmacy access could reduce demand for products of unknown origin sold online. Critics counter that wider availability through a medical channel can imply a level of validation the evidence does not support.

Both points can be true. Moving use from anonymous internet vendors to state-licensed pharmacies may improve traceability and clinician involvement. But a cleaner supply chain does not resolve whether a substance works, which patients face greater risks, what dose is appropriate or what long-term harms might emerge. Any interim policy therefore needs safeguards that address access and evidence separately.

Questions the final policy should answer

First, regulators should identify every covered peptide and route of administration. Injectable products carry different contamination and immune risks from topical or oral preparations. Second, the policy should specify testing standards for identity, potency, sterility, endotoxins and peptide-related impurities, along with recordkeeping that allows a product to be traced to its source.

Third, the government should make adverse-event reporting explicit for compounders and prescribers. A temporary access program can generate useful evidence only if outcomes are captured consistently. Reports should record the product source, concentration, route, dosing schedule and other drugs used, while protecting patient privacy. Aggregate findings should be released on a regular timetable.

Fourth, marketing restrictions must remain clear. Enforcement discretion for pharmacy compounding should not be treated as permission to claim that a peptide repairs tissue, builds muscle or treats disease without adequate evidence. Patients should receive written notice that the preparation is compounded, is not FDA-approved and has not undergone the same premarket review as an approved drug.

Fifth, the policy should explain its endpoint. A genuine interim measure needs an expiration date, criteria for renewal and a path to formal rulemaking or withdrawal. Otherwise, temporary discretion can become a durable policy without the public comment and evidentiary record that normally accompany a regulatory decision.

Patients and clinicians need precise language

The debate is complicated by the fact that “peptide” describes a broad class, not a single risk category. Insulin and several GLP-1 medicines are peptides with established approval records. Their existence does not validate unrelated experimental compounds. Likewise, concern about BPC-157 does not mean every peptide medicine is unsafe.

Athletes face an additional issue: BPC-157 is listed as a prohibited nonapproved substance under anti-doping rules, according to the U.S. Anti-Doping Agency's 2027 guidance. Legal access through a pharmacy would not automatically change sports eligibility rules.

The White House review is a procedural step, not a final decision. Until the policy text is released, claims about broad legalization or FDA endorsement go beyond the public record. The decisive test will be whether the administration pairs any access expansion with product-quality requirements, transparent patient warnings, systematic safety reporting and a timetable for obtaining the human evidence that remains missing.